Roche riled by NICE not recommending cancer drug

29 December 2016
nice-big

The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Kadcyla (trastuzumab emtansine), a breast cancer drug currently available through the UK’s Cancer Drugs Fund (CDF).

NICE, the cost-effectiveness watchdog for England and Wales, has reasoned that the drug does not work well enough to justify its high cost, even with the patient access scheme offered by Swiss pharma major Roche (ROG: SIX).

"We are surprised that NICE considered lapatinib in combination with capecitabine as the most relevant comparaThe or"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical